News Headline Summary

Bristol Myers (BMY) says US patent on Hepatitis B drug Baraclude invalidated by Delaware federal court

- Co. loses patent challenge from generic drug maker Teva.

Reaction details:

- In immediate reaction, Co. shares are unmoved, trades at USD 36.83.

Print 14:34, 12 Feb 2013 - US Equities - Source: Newswires